ATE283864T1 - Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor - Google Patents

Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor

Info

Publication number
ATE283864T1
ATE283864T1 AT92914056T AT92914056T ATE283864T1 AT E283864 T1 ATE283864 T1 AT E283864T1 AT 92914056 T AT92914056 T AT 92914056T AT 92914056 T AT92914056 T AT 92914056T AT E283864 T1 ATE283864 T1 AT E283864T1
Authority
AT
Austria
Prior art keywords
fragment
aqueous solution
von willebrand
willebrand factor
denaturant
Prior art date
Application number
AT92914056T
Other languages
English (en)
Inventor
David L Farb
Michael E Hrinda
Ted C K Lee
Christopher P Prior
Original Assignee
Aventis Behring L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring L L C filed Critical Aventis Behring L L C
Application granted granted Critical
Publication of ATE283864T1 publication Critical patent/ATE283864T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT92914056T 1991-06-20 1992-06-19 Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor ATE283864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71794291A 1991-06-20 1991-06-20
PCT/US1992/005215 WO1993000107A1 (en) 1991-06-20 1992-06-19 Therapeutic fragments of von willebrand factor

Publications (1)

Publication Number Publication Date
ATE283864T1 true ATE283864T1 (de) 2004-12-15

Family

ID=24884150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914056T ATE283864T1 (de) 1991-06-20 1992-06-19 Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor

Country Status (9)

Country Link
US (1) US5539086A (de)
EP (1) EP0590048B1 (de)
AT (1) ATE283864T1 (de)
AU (1) AU2253392A (de)
CA (1) CA2110585C (de)
DE (1) DE69233451T2 (de)
ES (1) ES2233924T3 (de)
MX (1) MX9203011A (de)
WO (1) WO1993000107A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US6821943B2 (en) 2001-03-13 2004-11-23 S. C. Johnson & Son, Inc. Hard surface antimicrobial cleaner with residual antimicrobial effect comprising an organosilane
AU2003223936A1 (en) * 2002-05-17 2003-12-02 Kobenhavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
AU2014202595A1 (en) * 2007-12-28 2014-06-05 Baxalta GmbH Recombinant VWF Formulations
TW201731488A (zh) * 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
HRP20130414T1 (en) * 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
HUE029454T2 (en) * 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
AU2016204172A1 (en) * 2016-06-20 2018-01-18 The University Of Sydney Allosteric regulation of haemostatic activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
ES2070116T3 (es) * 1986-05-30 1995-06-01 Scripps Research Inst Peptidos que inhiben la union del factor von willebrand.
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins

Also Published As

Publication number Publication date
EP0590048A4 (en) 1994-06-08
WO1993000107A1 (en) 1993-01-07
ES2233924T3 (es) 2005-06-16
DE69233451D1 (de) 2005-01-05
CA2110585C (en) 2004-10-12
EP0590048B1 (de) 2004-12-01
AU2253392A (en) 1993-01-25
MX9203011A (es) 1993-08-01
US5539086A (en) 1996-07-23
EP0590048A1 (de) 1994-04-06
DE69233451T2 (de) 2006-01-12
CA2110585A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
ATE283864T1 (de) Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
ATE226960T1 (de) Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
ATE364589T1 (de) Verfahren zur herstellung von hochreinen kristallen von glykolsäure
DE3680800D1 (de) Verfahren zur herstellung von (6r)-tetrahydro-l-biopterin.
ATE352569T1 (de) Verfahren zur abtrennung des alpha-1-proteinase inhibitors von einer cohn-paste, welche die fraktionen iv-1 + iv-4 enthält
ATE44236T1 (de) Verfahren zur herstellung eines hochgereinigten antihaemophilfaktor-konzentrats.
ATE137488T1 (de) Verfahren zur herstellung von reiner hydroxyessigsäure
SE8104482L (sv) Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
ATA278988A (de) Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
ATE96784T1 (de) Verfahren zur reinigung von tryptophan.
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
DE69523051D1 (de) Methode zur klärung von schlempen
ATE174601T1 (de) Verfahren zur herstellung von bisnoraldehyden aus bisnoralkohol
ATE108171T1 (de) Reinigung von 1,1-dichlor-1-fluorethan.
DE69413946D1 (de) Verfahren zur Herstellung von hochreiner 2,6-Naphthalindicarbonsäure
DE69637464D1 (de) Therapeutische fragmente des "von willebrand" faktors
ATE189680T1 (de) Verfahren zur quantitativen aufreinigung von glycolipiden
FR2610633B1 (fr) Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
ATE49185T1 (de) Verfahren zur herstellung von halogen-magnesium- alanat und dessen verwendung.
ATE213234T1 (de) Verfahren zur herstellung von 3-amino-1,2,4- benzotriazindioxide
ATE15052T1 (de) Verfahren zur herstellung von alpha-aspartylphenylalamin methylester.
ATE155481T1 (de) Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung
DE3780112D1 (de) Verfahren zur herstellung von penicillansaeure-derivaten.
ATE73820T1 (de) Verfahren zur herstellung eines hochgereinigten antihaemophilie-faktors.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0590048

Country of ref document: EP

EEFA Change of the company name